Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators

Open source

DOI: 10.1056/nejmoa1915745
Published: 2020 May 14
Container: The New England journal of medicine
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1915745,
  title = {Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.},
  author = {Finn RS and Qin S and Ikeda M and Galle PR and Ducreux M and Kim TY and Kudo M and Breder V and Merle P and Kaseb AO and Li D and Verret W and Xu DZ and Hernandez S and Liu J and Huang C and Mulla S and Wang Y and Lim HY and Zhu AX and Cheng AL and IMbrave150 Investigators},
  year = {2020},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa1915745},
  url = {https://doi.org/10.1056/nejmoa1915745}
}

RIS

TY  - JOUR
TI  - Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
AU  - Finn RS
AU  - Qin S
AU  - Ikeda M
AU  - Galle PR
AU  - Ducreux M
AU  - Kim TY
AU  - Kudo M
AU  - Breder V
AU  - Merle P
AU  - Kaseb AO
AU  - Li D
AU  - Verret W
AU  - Xu DZ
AU  - Hernandez S
AU  - Liu J
AU  - Huang C
AU  - Mulla S
AU  - Wang Y
AU  - Lim HY
AU  - Zhu AX
AU  - Cheng AL
AU  - IMbrave150 Investigators
PY  - 2020
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa1915745
UR  - https://doi.org/10.1056/nejmoa1915745
ER  -

APA

RS, F., S, Q., M, I., PR, G., M, D., TY, K., M, K., V, B., P, M., AO, K., D, L., W, V., DZ, X., S, H., J, L., C, H., S, M., Y, W., HY, L., AX, Z., AL, C., & Investigators, I. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa1915745

Source records

pubmed · retrieved 2026-11-10T08:16:29.956Z
europe-pmc · retrieved 2026-11-10T08:16:29.989Z
hal · retrieved 2026-11-10T08:16:30.031Z